Prion therapeutics: Lessons from the past.

Area of Science:

• Neuroscience
• Protein Misfolding Diseases
• Drug Discovery

Background:

• Prion diseases are incurable, zoonotic neurodegenerative diseases caused by misfolded prion proteins (PrPSc) in the central nervous system.
• Abnormal prion protein aggregation leads to severe brain damage and neurological symptoms.
• Existing therapeutic strategies aim to inhibit PrPSc formation, enhance clearance, or stabilize PrPC, with limited clinical success.

Approach:

• This review examines various anti-prion agents, including small molecules, antibodies, and serpin inhibitors.
• It discusses their structures, mechanisms of action, and toxicity profiles.
• The review highlights the challenges of in vivo efficacy, permeability, and toxicity in drug development for prion diseases.

Key Points:

• Numerous compounds show in vitro anti-prion activity, but few translate to in vivo efficacy.
• Toxicity and poor bioavailability are major hurdles for clinical translation.
• Recent trials of anti-prion antibodies, like PRN100, show promising results in CJD patients.

Conclusions:

• Understanding prion disease pathogenesis is crucial for developing effective treatments.
• Future anti-prion agents require reduced toxicity and enhanced bioavailability.
• New therapeutic strategies hold promise for treating prion diseases.